HYPE3
Hypera S.A.Report (Preview)
Detailed and complete analysis about this companyAccess full B3 reports
Full analysis — HYPE3 is available only for Premium subscribers.
With Premium you have access to detailed reports of all companies, with valuation and fair price.
Price Chart
Data provided by TradingView
Loading chart...
Analyst Recommendations
Valuation Multiples
Margins & Profitability
Growth
Corporate Risk
Dividends
Moving Averages
Average Volume
Dividend History (12m)
Price Evolution (12m)
Seasonality Study
Historical monthly performance of the asset over the last 11 years. Helps identify seasonal behavior patterns.
Avg Return (%)
High Frequency (%)
Best Month
2nd Best
High Frequency
High Frequency
Balance Sheet
| Period | Total Assets | Liabilities | Total Equity |
|---|---|---|---|
| 2025 | R$25.2B | R$12.6B | R$12.5B |
| 2024 | R$24.6B | R$12.5B | R$12.1B |
| 2023 | R$24.5B | R$13B | R$11.5B |
| 2022 | R$23.8B | R$13.1B | R$10.6B |
MyHub Discussion (0)
About the Company
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Market Data
- Market CapR$15.57B
- Min 52sMax 52sR$19.41R$30.00
- Average Volume4M